Boston Scientific Corporation has completed patient enrolment in the Evolve clinical trial to assess its fourth-generation Synergy coronary stent, which uses a platinum chromium alloy.

The stent, which is a tube used to keep arteries open for the treatment of coronary heart disease, will be evaluated through a randomised trial involving 291 patients in Europe, Australia and New Zealand.

Using the same proprietary platinum chromium alloy and design used on the Prous Element Stent, it is believed the instrument will offer faster and more comprehensive vessel healing.

"The Synergy stent is designed to combine the acute performance advantages of the platinum chromium Promus Element stent with an innovative bioabsorbable drug-polymer combination," said Keith D. Dawkins MD, chief medical officer of Boston Scientific's Cardiology, Rhythm and Vascular Group.

Last week, the medical device manufacturer announced the signing of a deal that will see it acquire Atritech, a private company specialising in atrial fibrillation based in Minnesota.

Source:



Boston Scientific completes enrolment in Evolve clinical trial to evaluate Synergy drug-eluting coronary stent (24/01/11)
 

© Adfero Ltd